We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Myoglobin Gene Mutation Causes New Muscle Disease

By LabMedica International staff writers
Posted on 08 Apr 2019
The cause of myoglobinopathy, a newly described disease of the muscles, has been traced to a mutation in the gene that encodes for the protein myoglobin (MB).

Myoglobin, like hemoglobin (Hb), is a cytoplasmic protein that binds oxygen on a heme group. More...
It harbors only one heme group, whereas hemoglobin has four. Although its heme group is identical to those in Hb, MB has a higher affinity for oxygen than does hemoglobin. This difference is related to its different role: whereas hemoglobin transports oxygen, myoglobin's function is to store oxygen. MB also acts as scavenger of free radicals and other reactive oxygen species, helping the cell to avoid damage caused by oxidative stress.

The newly characterized disease called myoglobinopathy manifests between the fourth and fifth decade of life. It causes a progressive weakness of the axial and limb muscles, and in more advanced stages affects the respiratory musculature and the heart.

Investigators at the Bellvitge Biomedical Research Institute (Barcelona, Spain) analyzed the genomes of fourteen members of six unrelated European families who displayed signs of myoglobinopathy. They identified an autosomal dominant myopathy with variable cardiac involvement and characteristic sarcoplasmic inclusions in skeletal and cardiac muscle that was linked to a recurrent substitution mutation in the MB gene.

Biochemical characterization revealed that the mutant myoglobin had altered oxygen binding, exhibited a faster heme dissociation rate, and had a lower reduction potential compared to wild-type myoglobin. Preliminary studies showed that effects of the myoglobin mutation caused elevated superoxide levels at the cellular level.

"This is the first time that a disease caused by a mutation in the myoglobin gene has been identified," said first author Dr. Montse Olivé, a physician and researcher in the institute of neuropathology at the Bellvitge Biomedical Research Institute. "We have identified the same mutation in several members of six unrelated European families, all of whom had the same symptoms and showed very characteristic lesions - called sarcoplasmic bodies - in muscle biopsies."

The genetic basis of myoglobinopathy was discussed in a paper published in the March 27, 2019, online edition of the journal Nature Communications.

Related Links:
Bellvitge Biomedical Research Institute


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.